Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 364

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 364
---
 extension. During this period, Kineta agrees not to engaged in discussions or negotiations with third parties regarding competing transactions and must notify Pacira of any unsolicited offers. In return, Pacira paid Kineta Chronic Pain a non-refundable and non-creditable exclusivity payment of $50,000.

On January 29, 2025, Kineta and GigaGen entered into the GigaGen Agreement.

On February 4, 2025, Kineta Chronic Pain and Pacira entered into the Pacira Asset Purchase Agreement.

On February 4, 2025, Kineta and HCRX entered into the HCRX Asset Purchase Agreement.

In April 2025, TuHURA and Kineta began discussing one or more potential amendments to the Merger Agreement to help facilitate the completion of the Mergers, particularly in light of the financing needs associated with the potential transaction. The original Merger Agreement entered into on December 11, 2024 (the “Original Merger Agreement”) provided that the amount of the Concurrent Investment would need to be a minimum of $35.0 million in net proceeds, that the Closing Adjusted Cash Consideration would be calculated with an initial base amount of $15.0 million, that the Initial Share Consideration would be $15.0 million, that the Kineta Delayed Share Consideration would be an amount equal to $5.0 million, and that the Estimated Net Working Capital Deficit would not exceed $12.0 million. In March and April 2025, the parties discussed the implications of changes in the capital markets since the date of the Original Merger Agreement that have affected TuHURA’s ability to enter into a definitive agreement for a Concurrent Investment. They also discussed the ongoing costs and expenses of Kineta continuing to operate as a publicly traded company, the cash needs associated with Kineta’s ongoing KVA12123 trial and development program, and the extended period of time that will be needed to satisfy closing conditions and complete the Mergers.

Based on these discussions, on April 14, 2025, TuHURA delivered to Kineta a term sheet setting forth certain proposed amendments to the Merger Agreement relating to, among other things, the size of the Concurrent Investment, balance of cash and share consideration in the Mergers, the extension of the End Date, and the availability of additional loans to Kineta. After delivery of the term sheet, Kineta communicated that it was in substantial agreement and requested that TuHURA convert